Ideaya Biosciences (IDYA) announced first-patient-in for a Phase 1 clinical trial combination study to evaluate IDE849, a delta-like ligand 3-targeting Topo-I-payload antibody drug conjugate program, and IDE161, a poly glycohydrolase inhibitor. The Phase 1 combination study will be evaluated in DLL3 upregulated solid tumor indications, including small cell lung cancer, neuroendocrine tumors, neuroendocrine carcinomas and melanoma.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences updates guidance related to timing of Phase 2/3 data release
- Ideaya Biosciences falls -6.0%
- IDEAYA Biosciences: Operational Trial Delay but High Conviction Buy Ahead of Key Darovasertib Readout
- IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating
- Ideaya Biosciences enrolls first patient in IDE892 trial